Overview and Scope
Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity.
Sizing and Forecast
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to aging population, prevalence of diabetes, awareness and early diagnosis, global initiatives in eye health, pharmaceutical innovations, patient advocacy and support..
The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $12.84 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine approaches, rising awareness in emerging markets, focus on combination therapies, integration with teleophthalmology services, global aging demographics.. Major trends in the forecast period include advancements in sustained-release drug delivery, integration of gene therapies, development of novel imaging technologies, personalized treatment approaches based on biomarkers, teleophthalmology for remote monitoring, advancements in artificial intelligence for diagnostics..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report
Segmentation & Regional Insights
The macular edema and macular degeneration market covered in this report is segmented –
1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration
3) By End User: Hospitals, Clinics, Other End Users
North America was the largest region in the macular edema and macular degeneration market market in 2023. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
Major Driver Impacting Market Growth
The rising diabetes population is expected to propel the growth of the macular edema and macular degeneration market going forward. Diabetes is a chronic medical condition characterized by high glucose (sugar) levels in the blood. Diabetes damages the blood vessels in the eye, which can result in macular edema and macular degeneration. For instance, in April 2023, according to a report published by The British Diabetic Association, a UK-based diabetes charity, the number of people living with diabetes has reached an all-time high of over 5 million, with 4.3 million people diagnosed with diabetes and an estimated 850,000 people living with the condition but not yet diagnosed. Further, more than 2.4 million people in the UK are at high risk of developing type 2 diabetes, and registration numbers for 2021-22 are up by 148,951 from 2020-21. Therefore, the rising diabetes population is driving the growth of the macular edema and macular degeneration market.
Key Industry Players
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmics Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited</b
The macular edema and macular degeneration market report table of contents includes:
1. Executive Summary
2. Macular Edema And Macular Degeneration Market Characteristics
3. Macular Edema And Macular Degeneration Market Trends And Strategies
4. Macular Edema And Macular Degeneration Market – Macro Economic Scenario
5. Global Macular Edema And Macular Degeneration Market Size and Growth
.
.
.
32. Global Macular Edema And Macular Degeneration Market Competitive Benchmarking
33. Global Macular Edema And Macular Degeneration Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Macular Edema And Macular Degeneration Market
35. Macular Edema And Macular Degeneration Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
